circadian rhythm raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-12-16 and is reviewed periodically as new material appears.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
=== Obsessive–compulsive disorder === Fluoxetine is effective in the treatment of obsessive–compulsive disorder (OCD). It is effective for treating OCD in children, adolescents and adults. The American Academy of Child and Adolescent Psychiatry state that SSRIs, including fluoxetine, should be used as first-line therapy in children, along with cognitive behavioral therapy (CBT), for the treatment of moderate to severe OCD.
==== Moving ==== Employer-paid moving expense benefits were temporarily considered taxable income to the employee, but they are now permanently taxable income. Moving expense benefits for employees who are active-duty members of the U.S. Armed Forces or members of the U.S. Intelligence Community continue to be tax-free to the employee.
In January 2023, Futurism broke the story that CNET had been using an undisclosed internal AI tool to write at least 77 of its stories; after the news broke, CNET posted corrections to 41 of the stories. In April 2023, Die Aktuelle published an AI-generated fake interview of Michael Schumacher. In May 2024, Futurism noted that a content management system video by AdVon Commerce, which had used generative AI to produce articles for many of the aforementioned outlets, appeared to show that they "had produced tens of thousands of articles for more than 150 publishers". In 2025, a report from the American Sunlight Project stated that Pravda network was publishing as many as 10,000 articles a day, and concluded that much of this content aimed to push Russian narratives into large language models through their training data. In June 2024, Reuters Institute published its Digital News Report for 2024. In a survey of people in America and Europe, Reuters Institute reports that 52% and 47% respectively are uncomfortable with news produced by "mostly AI with some human oversight", and 23% and 15% respectively report being comfortable. 42% of Americans and 33% of Europeans reported that they were comfortable with news produced by "mainly human with some help from AI". The results of global surveys reported that people were more uncomfortable with news topics including politics (46%), crime (43%), and local news (37%) produced by AI than other news topics. A 2025 Pew Research Survey found roughly half of all U.S.
Sources: en.wikipedia.org
Efforts to understand how proteins are encoded began after DNA's structure was discovered in 1953. The key discoverers, English biophysicist Francis Crick and American biologist James Watson, working together at the Cavendish Laboratory of the University of Cambridge, hypothesised that information flows from DNA and that there is a link between DNA and proteins. Soviet-American physicist George Gamow was the first to give a workable scheme for protein synthesis from DNA. He postulated that sets of three bases (triplets) must be employed to encode the 20 standard amino acids used by living cells to build proteins, which would allow a maximum of 43 = 64 amino acids (all permutations of the four bases, read three at a time). He named this DNA–protein interaction (the original genetic code) as the "diamond code". In 1954, Gamow created an informal scientific organisation the RNA Tie Club, as suggested by Watson, for scientists of different persuasions who were interested in how proteins were synthesised from genes. However, the club could have only 20 permanent members to represent each of the 20 amino acids; and four additional honorary members to represent the four nucleotides of DNA. The first scientific contribution of the club, later recorded as "one of the most important unpublished articles in the history of science" and "the most famous unpublished paper in the annals of molecular biology", was made by Crick.
Careful experiments were performed in which chemical reactions such as rusting were allowed to take place in sealed glass ampoules; it was found that the chemical reaction did not change the weight of the sealed container and its contents. Weighing of gases using scales was not possible until the invention of the vacuum pump in the 17th century. Once understood, the conservation of mass was of great importance in progressing from alchemy to modern chemistry. Once early chemists realized that chemical substances never disappeared but were only transformed into other substances with the same weight, these scientists could for the first time embark on quantitative studies of the transformations of substances. The idea of mass conservation plus a surmise that certain "elemental substances" also could not be transformed into others by chemical reactions, in turn led to an understanding of chemical elements, as well as the idea that all chemical processes and transformations (such as burning and metabolic reactions) are reactions between invariant amounts or weights of these chemical elements. Following the pioneering work of Lavoisier, the exhaustive experiments of Jean Stas supported the consistency of this law in chemical reactions, even though they were carried out with other intentions. His research indicated that in certain reactions the loss or gain could not have been more than 2 to 4 parts in 100,000. The difference in the accuracy aimed at and attained by Lavoisier on the one hand, and by Edward W. Morley and Stas on the other, is enormous.
=== Technical issues during the flight === On the 19th orbit, the first sign of trouble appeared when the spacecraft 0.05 g (0.5 m/s2) light came on. However, this turned out to be a faulty indicator, and the spacecraft was not reentering. On the 20th orbit, Cooper lost all attitude readings. The 21st orbit saw a short-circuit occur in the bus bar serving the 250 VA (115 V, 400 Hz) main inverter. This left the automatic stabilization and control system without electric power. On the 21st orbit, John Glenn on board the tracking ship Coastal Sentry Quebec near Kyushu, Japan, helped Cooper prepare a revised checklist for retrofire. Due to the system malfunctions, many of the steps would have to be done manually. Only Hawaii and Zanzibar were in radio range on this last orbit, but communications were good. Cooper noted that the carbon dioxide level was rising in the cabin and in his spacesuit. He told Carpenter as he passed over Zanzibar, "Things are beginning to stack up a little." Throughout the problems, Cooper remained cool, calm and collected. Cooper did not experience much of an appetite during the flight and ate only because it was scheduled. The food containers and water dispenser system proved unwieldy and he was not able to properly prepare freeze-dried food packages, so he limited his consumption to cubed food and bite-sized sandwiches. Cooper found the cubed food largely unpalatable, which contributed to his lack of eating.
The HAIR-AN syndrome is a rare subtype of polyendocrine metabolic ovarian syndrome (PMOS) characterized by hyperandrogenism (HA), insulin resistance (IR) and acanthosis nigricans (AN). The symptoms of the HAIR-AN syndrome are largely due to severe insulin resistance, which can be secondary to blocking antibodies against the insulin receptor or genetically absent/reduced insulin receptor number/function. Insulin resistance leads to hyperinsulinemia which, in turn, leads to an excess production of androgen hormones by the ovaries. High levels of androgen hormones (hyperandrogenism) in females causes excessive hair growth, acne and irregular menstruation. Patients with both underlying mechanisms of insulin resistance may have more severe hyperandrogenism. Insulin resistance is also associated with diabetes, heart disease and excessive darkening of the skin (acanthosis nigricans)
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.